Daniel P. Petrylak, MD, presented “FDA Approves Pembrolizumab for New Indication of NMIBC” for the Grand Rounds in Urology audience in January 2020.
How to cite: Petrylak, Daniel P. “FDA Approves Pembrolizumab for New Indication of NMIBC” January, 2020. Accessed Nov 2024. https://grandroundsinurology.com/late-breaking-fda-approves-pembrolizumab-for-new-indication-of-nmibc/
FDA Approves Pembrolizumab for New Indication of NMIBC – Summary:
Daniel P. Petrylak, MD, discusses the recent FDA approval of the checkpoint inhibitor pembrolizumab for treating cystectomy-ineligible (or those who have refused cystectomy) non-muscle invasive bladder cancer patients who have also failed BCG. He details the prior lack of available treatment for this disease, explains the function of the drug as a checkpoint inhibitor, and describes the study that led to the drug’s approval.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee.
